Effectiveness of Laying-on-of-hands for Sickle Cell Disease
NCT ID: NCT01518218
Last Updated: 2015-04-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
40 participants
INTERVENTIONAL
2006-03-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD
NCT04388241
Feasibility of a Stress Reduction Intervention Study in Sickle Cell Disease
NCT02501447
Stigma, Self-management, & Quality of Life in SCD
NCT03488264
Patient-Provider Tools to Improve the Transition to Adult Care in Sickle Cell Disease
NCT02200510
A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study
NCT00895154
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
laying-on-of-hands
Patients of this arm received laying-on-of-hands twice a day (45 minutes each) every weekday for 1year, and received conventional medical treatment if necessary.
laying-on-of-hands
The intervention group received laying-on-of-hands every weekday for 1 year along with conventional medicine. The control group did not undergo any alternatives to OPT.
control group
Patients of this arm did not receive any alternatives other than conventional treatment.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
laying-on-of-hands
The intervention group received laying-on-of-hands every weekday for 1 year along with conventional medicine. The control group did not undergo any alternatives to OPT.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* those able to receive laying-on-of-hands every weekday for 1 year
* those able to receive conventional medical treatment whenever necessary
* those able to receive blood test at the beginning, after 6 month and after 1 year
Exclusion Criteria
3 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MOA Health Science Foundation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kiyoshi Suzuki
president
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kodondi K Koto, MD, PhD
Role: STUDY_DIRECTOR
The Institute of Scientific Research for Health, Kinshasa
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The national medical center for sickle cell disease
Kinshasa, , Democratic Republic of the Congo
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Minga TM, Koto FK, Egboki H, Suzuki K. Effectiveness of biofield therapy for individuals with sickle cell disease in Africa. Altern Ther Health Med. 2014 Jan-Feb;20(1):20-6.
Related Links
Access external resources that provide additional context or updates about the study.
MOA International Corporation
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MOA-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.